FPT
28.2.2024 10:31:29 CET | Business Wire | Press release
Global IT corporation FPT recently signed a Memorandum of Understanding (MoU) with the multinational industrial technology conglomerate Siemens, fostering collaboration and mutually beneficial business opportunities in advancing the manufacturing sector and semiconductor chip production while accelerating digital transformation globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240228584022/en/
Nguyen The Phuong, Executive Vice President and Chief Finance Officer of FPT Corporation (L), Pham Thai Lai, President & CEO of Siemens ASEAN & Vietnam (R), and both parties’ representatives. (Photo: Business Wire)
FPT and Siemens will join forces in areas such as smart infrastructure, green and intelligent data centers, digital industrial solutions, automotive software development, and digital transformation. Built on the successful partnership on MindSphere IoT Operating System since 2017, the new agreement focuses on strengthening engagement and competencies in digital transformation services for both sides and their clients worldwide, as well as opening up new business opportunities.
Harnessing FPT's robust expertise and high-quality workforce, FPT aspires to become the Global SI Partner for Siemens’ low-code platform - Mendix, and Engineering Services Provider for Siemens EDA, focusing on AUTOSAR projects.
Siemens also invites FPT to join its Xcelerator ecosystem to accelerate digital transformation with Siemens' solutions and applications. Additionally, the two parties will further expand collaboration in the smart infrastructure domain, with Siemens targeting to be the preferred supplier for FPT’s data center network and its sustainable infrastructure development projects in Vietnam.
Leveraging its profound technology foundation in the digital ecosystem, Cloud, and low-code, Siemens commits to aiding FPT with access to training and knowledge-sharing on a large scale. The German powerhouse will also provide support and explore collaboration with FPT in semiconductor design and manufacturing, one of FPT’s pivotal areas for future growth. As a leading chipmaking company in Vietnam, FPT also aims to supply semiconductor chips to Siemens.
Speaking at the signing ceremony, Dr. Truong Gia Binh, FPT Chairman & Founder, said: “FPT focuses on five keywords: Digital transformation, Green transformation, Artificial Intelligence, Automotive, and Semiconductor. Our greatest resource is our talented people, with 32,000 digital transformation experts working across the globe. In the future, we plan to invest in AI supercomputers and workforce training and development, prioritizing NVIDIA certifications and advancing innovations in industries such as automotive and semiconductor. I believe these will be the stepping stones to enhance cooperation between FPT and Siemens.”
Mr. Roland Busch, Chairman and CEO of Siemens AG, affirmed that FPT and Siemens have many commonalities: “Siemens has extensive experience in the semiconductor industry, and we are confident in our capability to provide FPT with technological support. Furthermore, Siemens boasts expertise in various domains, including smart infrastructure and digital industrial solutions. We are positioned to leverage these technologies to enhance product adaptability in daily life. Consequently, Siemens is fully prepared to collaborate closely with FPT in their future endeavors, offering comprehensive support and innovative solutions.”
Siemens and FPT have years of experience in successful collaboration, varying across sectors and industries. With a track record of success and extensive experience, FPT has established itself as a world-class technology enabler for complex business challenges and opportunities. Post surpassing one billion USD in revenue from global IT services in 2023, the Vietnam-headquartered tech corporation aims to achieve USD 5 billion in revenue from global IT services by 2030 and reach billion-dollar milestones from a single market, a single vertical industry and a single contract.
The signing ceremony took place in Hanoi, Vietnam, on 26 February 2024, with the participation of Dr. Roland Busch, Siemens AG President & Chief Executive Officer; Dr. Pham Thai Lai, President & Chief Executive Officer of Siemens ASEAN & Vietnam; Dr. Truong Gia Binh, FPT Corporation Chairman, Mr. Nguyen The Phuong, FPT Corporation Executive Vice President and Chief Finance Officer, as well as both companies’ senior leaders.
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of US$2.17 billion and 70,000+ employees. For more information, please visit https://fpt.com.vn/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228584022/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom